Loading patent…
AssigneeIncyte Pharmaceuticals, Inc.
InventorsOlga Bandman, Surya K. Goli, Lynn E. Murry
Estimating the term…
The present invention provides a human tumor-associated Kazal inhibitor (TAKI) and polynucleotides which identify and encode TAKI. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TAKI and a method for producing TAKI. The invention also provides for agonists, antibodies, or antagonists specifically binding TAKI, and their use, in the prevention and treatment of intestinal diseases including cancer. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TAKI for the treatment of diseases associated with the expression of TAKI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TAKI.
A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:1.
An isolated and purified polynucleotide sequence comprising SEQ ID NO:2.
A polynucleotide sequence which is complementary to SEQ ID NO:2.
A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, the method comprising the steps of:
Dependencies are inferred from the claim text.